These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18220664)

  • 1. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
    Norris SL; Carson S; Roberts C
    Curr Diabetes Rev; 2007 May; 3(2):127-40. PubMed ID: 18220664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
    Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
    Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Bundhun PK; Janoo G; Teeluck AR; Huang F
    BMC Pharmacol Toxicol; 2017 Oct; 18(1):66. PubMed ID: 29058622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study.
    Kikuchi M; Kaku K; Odawara M; Momomura S; Ishii R
    Curr Med Res Opin; 2012 Jun; 28(6):1007-16. PubMed ID: 22587483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.
    Chapell R; Gould AL; Alexander CM
    Diabetes Obes Metab; 2009 Nov; 11(11):1009-16. PubMed ID: 19614948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
    Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
    BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.
    Louisa M; Takeuchi M; Takeuchi M; Nafrialdi ; Setiabudy R
    Acta Med Indones; 2011 Jan; 43(1):39-52. PubMed ID: 21339545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
    Sheth SH; Larson RJ
    BMC Infect Dis; 2010 Jun; 10():183. PubMed ID: 20573187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
    Colmers IN; Bowker SL; Majumdar SR; Johnson JA
    CMAJ; 2012 Sep; 184(12):E675-83. PubMed ID: 22761478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
    Loke YK; Singh S; Furberg CD
    CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.
    Mendes D; Alves C; Batel-Marques F
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1259-70. PubMed ID: 26376779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "glitazones": rosiglitazone and pioglitazone.
    Papoushek C
    J Obstet Gynaecol Can; 2003 Oct; 25(10):853-7. PubMed ID: 14532954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
    Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
    Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.